◈ Nootpedia
Compact view
Research pass: medium SARM · Oral SKIP-FOR-NOW HIGH

LGD-4033 (Ligandrol)

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW HIGH

HPG-axis suppression in still-developing 20yo endocrine + brain-development concerns + documented hepatotoxicity case reports + FDA prohibited + research-chem product identity questionable. Nothing about Dylan's stated priorities (brain #1, MMA performance) is meaningfully advanced by a body-comp anabolic. Verdict would change only at age 30+ with bloodwork-supported HPG recovery plan, post-cycle therapy access, and verified product COA — and even then the evidence/risk ratio is poor vs alternatives.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-AT-

    HPG-axis suppression at this age is a direct hit on still-finalizing endocrine development. Brain-development at 20 is not "done" — prefrontal cortex maturation continues to ~25 and androgen signaling participates in CNS development. Hepatotoxicity case reports are concentrated in this exact demographic. Body-composition gains are not on Dylan's stated priority list (#1 brain, #2 MMA performance, #3 longevity, #4 recovery — aesthetic/mass explicitly downstream). Untested status removes WADA argument but does not remove physiology.

  • 30-50, executive maintenance
    WATCH-LIST

    → still SKIP-FOR-NOW for most; only consider if hypogonadal with bloodwork support and even then enclomiphene or TRT under endocrinologist supervision is preferred over SARMs.

  • 50+, mild cognitive decline
    N

    a cognitive-decline tool. Off-target.

  • Anxiety-prone
    SKIP

    mood disturbance + cycle-end depression risk.

  • High athletic load, tested status
    SKIP-PERMANENT

    WADA Prohibited.

  • Sleep-disordered
    O

    (no sleep relevance).

  • Recovery-focused (post-injury, post-illness)
    WATCH-LIST

    narrowly — Phase 2 trials targeted hip-fracture recovery, but ostarine (better safety profile) or proper TRT are preferred clinical tools.

  • Strength/anabolic-focused, age 25+ with full HPG bloodwork + PCT plan
    OPTIONAL-ADD

    even here the hepatotoxicity tail risk and product-identity risk make it a poor risk-adjusted choice vs alternatives (TRT under physician care, enclomiphene, or simply not using).

▸ Subjective experience (deep)

Per user reports (forums, podcast interviews, case reports):

  • Onset: Body-comp changes appear by week 2-3 (water + early lean mass).
  • Peak: Weeks 4-8 — reported strength bump, easier recomposition, slight aggression/drive uptick.
  • Cycle-end: Libido drop, mild lethargy, "flat" mood, sometimes depressive symptoms as endogenous testosterone bottoms out. Erectile function commonly affected.
  • Recovery: Weeks to months for natural test to return; many users run a SERM PCT (enclomiphene 12.5-25 mg/day or clomid 25-50 mg/day for 4-6 weeks) to accelerate. Some users report incomplete recovery on repeat cycles.
  • Highly variable because (a) research-chem product identity is unreliable and (b) users frequently stack with other SARMs or compounds.
▸ Tolerance + cycling deep dive
  • Tolerance buildup: Not classical pharmacological tolerance — issue is HPG suppression, which forces cycling rather than continuous use.
  • Recommended cycle (research-chem community): 8 weeks on, 4-6 weeks PCT, then 8+ weeks fully off before considering another cycle.
  • Reset protocol: SERM PCT (enclomiphene/clomid/tamoxifen). Bloodwork-confirmed return to baseline LH/FSH/testosterone before any subsequent cycle. Many never fully recover on repeat cycling.
▸ Stacking deep dive

Synergistic with

(Documented for context. Stacking SARMs amplifies suppression and hepatotoxicity risk and is not recommended.)

  • enclomiphene: Used as PCT to restart HPG axis post-cycle — selective ER antagonist at hypothalamus, drives LH/FSH back up.
  • Creatine, protein: Standard anabolic supports; pharmacologically unrelated, no interaction.

Avoid stacking with

  • ostarine: Stacking SARMs compounds HPG suppression and hepatotoxicity — not additive in benefit, multiplicative in risk.
  • rad-140: Same — RAD-140 is more suppressive than LGD; stacking is the worst-of-both.
  • Other 17α-alkylated oral anabolics (winstrol, anavar, dianabol): Hepatotoxic stacking.
  • Acetaminophen/paracetamol regular use: Liver burden compounding.
  • Heavy alcohol: Liver burden compounding (Dylan is zero-alcohol — non-issue, but flagged generically).
  • Statins: Liver enzyme monitoring becomes confounded.

Neutral / safe co-administration

  • Most of Dylan's V4 stack (DHA, magnesium, citicoline, NAC, PS, curcumin, rhodiola, theanine, glycine, D3+K2, beta-alanine, vitamin C) does not interact pharmacodynamically. NAC and curcumin are mildly hepatoprotective, which is incidental — does not justify the risk.
▸ Drug interactions deep dive
  • CYP3A4: LGD-4033 is metabolized substantially by CYP3A4; strong inducers (rifampin, St John's wort) reduce exposure, strong inhibitors (ketoconazole, grapefruit, ritonavir) increase exposure and hepatotoxicity risk.
  • Warfarin/anticoagulants: Theoretical interaction via hepatic enzyme effects; monitor INR.
  • Insulin/glucose-lowering: Anabolic agents can modestly improve insulin sensitivity — monitor if diabetic.
  • No documented interactions with modafinil, racetams, or peptides in Dylan's V5 plan, but co-administration data is sparse.
▸ Pharmacogenomics
  • CYP3A4/3A5 polymorphisms affect exposure — fast metabolizers may need higher doses (and accept higher metabolite burden); slow metabolizers face elevated AUC and hepatotoxicity risk.
  • AR CAG repeat length modulates androgen sensitivity — shorter repeats = higher sensitivity to anabolic AND suppressive effects.
  • HSD3B1 variant alters androgen metabolism — relevant for prostate concerns.
  • Dylan's 23andMe results (June 2026 window) will provide CYP3A4/3A5 and AR CAG data — but this does not change the SKIP verdict, since suppression is mechanism-intrinsic.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research-chem Various (Chemyo, Sports Technology Labs, Umbrella Labs, etc.) $30-100 / 30 mL bottle (10 mg/mL liquid) or 60-90 caps Low-Medium "For research only" labeling. COA quality varies widely. Independent third-party testing (e.g., via SARMs.io community) regularly finds underdosed, overdosed, or substituted products.
FDA-approved Rx None N/A N/A No approved indication in any country. Viking's VK5211 program is in trials only.
Gray-market international Various Variable Low Customs seizure risk; product identity questionable.

Sourcing assessment: Even if SKIP verdict were lifted, product identity is the largest uncontrolled risk. Multiple FDA warning letters (2017, 2021) cite products labeled as LGD-4033 actually containing other SARMs, prohormones, or contaminants.

▸ Biomarkers to track (deep)

(Hypothetical — not recommending use.)

  • Baseline (before starting): Total testosterone, free testosterone, SHBG, LH, FSH, estradiol (sensitive assay), full lipid panel, CMP including ALT/AST/GGT/total bilirubin/albumin, CBC with hematocrit, PSA, fasting glucose + HbA1c.
  • During use: ALT/AST/GGT/bilirubin every 2 weeks; lipid panel at week 4 and week 8; testosterone/LH/FSH at week 4 and week 8.
  • Post-cycle: Weekly LH/FSH/total + free testosterone until baseline restored; lipid panel at PCT week 4 and again 4 weeks post-PCT; ALT/AST 4 weeks post-PCT.
▸ Controversies / open debates Live debate
  • "Selectivity" claim vs reality: Marketing positions SARMs as androgenic-side-effect-free; clinical data shows AR signaling in hypothalamus and liver is unavoidable. Selectivity is graded, not binary.
  • Hepatotoxicity — drug effect vs product contamination: Forum users argue cases are due to bad research-chem products, not LGD itself. LiverTox and JAMA reviewers note the pattern is consistent enough across cases to suggest the parent compound contributes.
  • Recovery completeness: Forum lore says "easy recovery with PCT"; clinical case reports include young men with persistent hypogonadism after repeat cycles. Truth probably lies in dose × duration × individual susceptibility.
  • Phase 2 (Viking VK5211) trial signal: Hip-fracture muscle-wasting trial showed statistically significant lean-mass gain. Whether this translates to a meaningful clinical product remains undetermined — Viking's pipeline has been intermittent.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-AT-20 HIGH. Combination of HPG-axis suppression in developing 20yo + hepatotoxicity case reports + brain-development concerns + FDA prohibited + research-chem product identity risk + body-comp goal not on Dylan's priority list. Verdict would shift only at age 30+, with bloodwork-supported recovery plan, COA-verified product, and a stronger justification than aesthetics.
▸ Open questions / gaps Open
  • Long-term (>1 year, multi-cycle) HPG recovery data in healthy young men — does not exist in controlled form.
  • True hepatotoxicity incidence rate at therapeutic dose using verified-pure product — unanswerable while sourcing is research-chem only.
  • AR CAG repeat × LGD response — would refine individual dose-response but does not change suppression mechanism.
  • Whether Viking VK5211 reaches FDA approval and at what indication — would change sourcing landscape but not the SKIP-at-20 logic.
▸ Sources (full, with our context)
Back to compact view